Upstream Bio Analyst Price Targets - Benzinga

SPY777.55−0.07%QQQ742.94−0.42%BTC/USD83,539.58+2.21%DIA518.03+0.02%GLD381.95−0.05%TLT78.42+0.47%

Upstream Bio Inc

UPBNASDAQ

Trade with Public

Trade with Public

$4.04

-0.13-3.24%

Last update: Oct 13, 10:39 AM

$4.25

0.081.92%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Upstream Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Upstream Bio (UPB).

Price Target Range — 5 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingOutperform# Analysts9Avg. Consensus PT$36Upside to Avg. PT+795.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$36
Aug 14, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$8→$9
Aug 12, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$43→$25
Jun 12, 2026	JP Morgan	Tessa Romero	Downgrade	Overweight→Neutral	$35→$8
Jun 3, 2026	HC Wainwright & Co.	Matthew Caufield	Initiate	Buy	$36
May 14, 2026	Mizuho	Joseph Catanzaro	PT Cut	Outperform	$51→$50
Mar 27, 2026	Evercore ISI Group	Cory Kasimov	Downgrade	Outperform→In-Line	$40→$15
Dec 18, 2025	Mizuho	Joseph Catanzaro	Initiate	Outperform	$51
Dec 2, 2025	LifeSci Capital	—	Initiate	Outperform	$43
Nov 18, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$40
Oct 14, 2025	Truist Securities	Danielle Brill	Initiate	Buy	$47
Nov 5, 2024	JP Morgan	Tessa Romero	Initiate	Overweight	$38
Nov 5, 2024	William Blair	Matt Phipps	Initiate	Outperform	—
Nov 5, 2024	TD Cowen	Yaron Werber	Initiate	Buy	—
Nov 5, 2024	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$75

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9

JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25

Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.

Benzinga Newsdesk

PRO
JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8

JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50

Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.

Benzinga Newsdesk